Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated:  10/19/2015
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
mi
from
Sleepy Hollow, NY
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Status: Enrolling
Updated: 10/19/2015
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated:  10/19/2015
University of Chicago
mi
from
Chicago, IL
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated: 10/19/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated:  10/19/2015
Barnes-Jewish Hospital
mi
from
St.Louis, MO
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated: 10/19/2015
Barnes-Jewish Hospital
mi
from
St.Louis, MO
Click here to add this to my saved trials
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated:  10/19/2015
Columbia University
mi
from
New York, NY
Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus
Endoscopic Resection or Ablation for Patients With Dysplasia or Intramucosal Cancer in Barrett's Esophagus
Status: Enrolling
Updated: 10/19/2015
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors
Status: Enrolling
Updated:  10/19/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors
Status: Enrolling
Updated: 10/19/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors
Status: Enrolling
Updated:  10/19/2015
Wisconsin Clinical Cancer Center
mi
from
Milwaukee, WI
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors
Status: Enrolling
Updated: 10/19/2015
Wisconsin Clinical Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Childrens National Medical Center
mi
from
Washington,
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
National Cancer Institute Pediatric Oncology Branch
mi
from
Bethesda, MD
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Children's Hospital of Pittsburgh of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Baylor College of Medicine
mi
from
Houston, TX
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Lurie Children's Hospital- Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis
Status: Enrolling
Updated:  10/19/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis
Status: Enrolling
Updated: 10/19/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Upper Extremity Lymphatic Mapping for Breast Cancer Patients: A Pilot Study
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Upper Extremity Lymphatic Mapping for Breast Cancer Patients
Upper Extremity Lymphatic Mapping for Breast Cancer Patients: A Pilot Study
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Phase II Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 10/19/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Southern California Permanente Medical Group
mi
from
Downey, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Southern California Permanente Medical Group
mi
from
Downey, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Children's Hospital Central California
mi
from
Madera, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Children's Hospital Central California
mi
from
Madera, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Children's Hospital and Research Center Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Children's Hospital of Orange County
mi
from
Orange, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Rady Children's Hospital - San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Connecticut Children's Medical Center
mi
from
Hartford, CT
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Alfred I. duPont Hospital for Children
mi
from
Wilmington, DE
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Childrens National Medical Center
mi
from
Washington,
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Miami Children's Hospital
mi
from
Miami, FL
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Miami Children's Hospital
mi
from
Miami, FL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Nemours Children's Clinic - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Nemours Children's Clinic - Pensacola
mi
from
Pensacola, FL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Tripler Army Medical Center
mi
from
Honolulu, HI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Tripler Army Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Saint Luke's Mountain States Tumor Institute
mi
from
Boise, ID
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Saint Jude Midwest Affiliate
mi
from
Peoria, IL
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Kosair Children's Hospital
mi
from
Louisville, KY
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Hurley Medical Center
mi
from
Flint, MI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Hurley Medical Center
mi
from
Flint, MI
Click here to add this to my saved trials
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated:  10/20/2015
Helen DeVos Children's Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors
Status: Enrolling
Updated: 10/20/2015
Helen DeVos Children's Hospital at Spectrum Health
mi
from
Grand Rapids, MI
Click here to add this to my saved trials